Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Lung Cancer

  Free Subscription


17.06.2019

1 AJR Am J Roentgenol
1 Ann Oncol
4 Anticancer Res
4 BMC Cancer
2 Cancer Chemother Pharmacol
2 Cancer Lett
3 Clin Lung Cancer
2 Eur J Cancer
1 Int J Cancer
1 Int J Radiat Oncol Biol Phys
2 J Cancer Res Clin Oncol
1 J Clin Oncol
1 J Thorac Cardiovasc Surg
5 J Thorac Oncol
16 Lung Cancer
1 Nat Rev Cancer
1 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    AJR Am J Roentgenol

  1. HASSANI C, Ronco A, Prosper AE, Dissanayake S, et al
    Forward-Projected Model-Based Iterative Reconstruction in Screening Low-Dose Chest CT: Comparison With Adaptive Iterative Dose Reduction 3D.
    AJR Am J Roentgenol. 2018 Jul 24:1-9. doi: 10.2214/AJR.17.19245.
    PubMed     Text format     Abstract available


    Ann Oncol

  2. FRUH M, Peters S
    EGFR mutation subtype impacts efficacy of immune checkpoint inhibitors in Non-Small Cell Lung Cancer.
    Ann Oncol. 2019 Jun 14. pii: 5518918. doi: 10.1093.
    PubMed     Text format    


    Anticancer Res

  3. CHASZCZEWSKA-MARKOWSKA M, Kosacka M, Chryplewicz A, Dyla T, et al
    ECCR1 and NFKB2 Polymorphisms as Potential Biomarkers of Non-small Cell Lung Cancer in a Polish Population.
    Anticancer Res. 2019;39:3269-3272.
    PubMed     Text format     Abstract available

  4. HAQUE W, Verma V, Butler EB, Teh BS, et al
    Patterns of End-of-Life Oncologic Care for Stage IV Non-small Cell Lung Cancer in the United States.
    Anticancer Res. 2019;39:3137-3140.
    PubMed     Text format     Abstract available

  5. WOUTERS A, Durieux V, Kolivras A, Meert AP, et al
    Bullous Lupus Under Nivolumab Treatment for Lung Cancer: A Case Report With Systematic Literature Review.
    Anticancer Res. 2019;39:3003-3008.
    PubMed     Text format     Abstract available

  6. TAKAHASHI S, Go T, Anada M, Kinoshita T, et al
    Comparison Between Stereotactic and Conventional Radiotherapy for Solitary Lung Tumor After Resection of Lung Cancer.
    Anticancer Res. 2019;39:2957-2962.
    PubMed     Text format     Abstract available


    BMC Cancer

  7. KANG G, Chen K, Yang F, Chuai S, et al
    Monitoring of circulating tumor DNA and its aberrant methylation in the surveillance of surgical lung Cancer patients: protocol for a prospective observational study.
    BMC Cancer. 2019;19:579.
    PubMed     Text format     Abstract available

  8. SUN X, Roudi R, Dai T, Chen S, et al
    Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
    BMC Cancer. 2019;19:558.
    PubMed     Text format     Abstract available

  9. TSUNODA A, Morikawa K, Inoue T, Miyazawa T, et al
    A prospective observational study to assess PD-L1 expression in small biopsy samples for non-small-cell lung cancer.
    BMC Cancer. 2019;19:546.
    PubMed     Text format     Abstract available

  10. NUKII Y, Miyamoto A, Mochizuki S, Moriguchi S, et al
    Pneumatosis intestinalis induced by osimertinib in a patient with lung adenocarcinoma harbouring epidermal growth factor receptor gene mutation with simultaneously detected exon 19 deletion and T790 M point mutation: a case report.
    BMC Cancer. 2019;19:186.
    PubMed     Text format     Abstract available


    Cancer Chemother Pharmacol

  11. GOEL S, Swami U, Kumar K, Dittrich C, et al
    A phase 1b, multicenter, open-label, dose-finding study of eribulin in combination with carboplatin in advanced solid tumors and non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2019 Jun 12. pii: 10.1007/s00280-019-03877.
    PubMed     Text format     Abstract available

  12. HOSOYA K, Fujimoto D, Kawachi H, Sato Y, et al
    Ineligibility for the PACIFIC trial in unresectable stage III non-small cell lung cancer patients.
    Cancer Chemother Pharmacol. 2019 Jun 14. pii: 10.1007/s00280-019-03885.
    PubMed     Text format     Abstract available


    Cancer Lett

  13. LI D, Wang H, Ding Y, Zhang Z, et al
    Targeting the NRF-2/RHOA/ROCK signaling pathway with a novel aziridonin, YD0514, to suppress breast cancer progression and lung metastasis.
    Cancer Lett. 2018;424:97-108.
    PubMed     Text format     Abstract available

  14. ZHANG YC, Zhou Q, Wu YL
    Clinical management of third-generation EGFR inhibitor-resistant patients with advanced non-small cell lung cancer: current status and future perspectives.
    Cancer Lett. 2019 Jun 12. pii: S0304-3835(19)30346.
    PubMed     Text format     Abstract available


    Clin Lung Cancer

  15. MARTIN J, Lehmann A, Klauschen F, Hummel M, et al
    Clinical Impact of Rare and Compound Mutations of Epidermal Growth Factor Receptor in Patients With Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2019 May 11. pii: S1525-7304(19)30103.
    PubMed     Text format     Abstract available

  16. TEGLASI V, Pipek O, Lozsa R, Berta K, et al
    PD-L1 Expression of Lung Cancer Cells, Unlike Infiltrating Immune Cells, Is Stable and Unaffected by Therapy During Brain Metastasis.
    Clin Lung Cancer. 2019 May 15. pii: S1525-7304(19)30112.
    PubMed     Text format     Abstract available

  17. ALBERTS L, Wolff HB, Kastelijn EA, Lagerwaard FJ, et al
    Patient-reported Outcomes After the Treatment of Early Stage Non-small-cell Lung Cancer With Stereotactic Body Radiotherapy Compared With Surgery.
    Clin Lung Cancer. 2019 Apr 25. pii: S1525-7304(19)30081.
    PubMed     Text format     Abstract available


    Eur J Cancer

  18. COURAUD S, Barlesi F, Fontaine-Deraluelle C, Debieuvre D, et al
    Clinical outcomes of non-small-cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France study.
    Eur J Cancer. 2019;116:86-97.
    PubMed     Text format     Abstract available

  19. RECK M, Schenker M, Lee KH, Provencio M, et al
    Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial.
    Eur J Cancer. 2019;116:137-147.
    PubMed     Text format     Abstract available


    Int J Cancer

  20. TAKASHIMA Y, Kikuchi E, Kikuchi J, Suzuki M, et al
    Bromodomain and Extraterminal Domain Inhibition Synergizes with WEE1-Inhibitor AZD1775 Effect by Impairing Non-Homologous End Joining and Enhancing DNA Damage in Non-Small Cell Lung Cancer.
    Int J Cancer. 2019 Jun 14. doi: 10.1002/ijc.32515.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  21. LADBURY CJ, Rusthoven CG, Camidge DR, Kavanagh BD, et al
    Impact of Radiation Dose to the Host Immune System on Tumor Control and Survival for Stage III Non-Small Cell Lung Cancer Treated with Definitive Radiotherapy.
    Int J Radiat Oncol Biol Phys. 2019 Jun 5. pii: S0360-3016(19)30818.
    PubMed     Text format     Abstract available


    J Cancer Res Clin Oncol

  22. KOH YW, Han JH, Haam S, Jung J, et al
    ALDH1 expression correlates with an epithelial-like phenotype and favorable prognosis in lung adenocarcinoma: a study based on immunohistochemistry and mRNA expression data.
    J Cancer Res Clin Oncol. 2019;145:1427-1436.
    PubMed     Text format     Abstract available

  23. SCHULER M, Tan EH, O'Byrne K, Zhang L, et al
    First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression.
    J Cancer Res Clin Oncol. 2019;145:1569-1579.
    PubMed     Text format     Abstract available


    J Clin Oncol

  24. ZHONG WZ, Chen KN, Chen C, Gu CD, et al
    Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study.
    J Clin Oncol. 2019 Jun 13:JCO1900075. doi: 10.1200/JCO.19.00075.
    PubMed     Text format     Abstract available


    J Thorac Cardiovasc Surg

  25. LUI NS
    Commentary: Pleomorphic carcinoma: An aggressive type of non-small cell lung cancer that should be treated like the others.
    J Thorac Cardiovasc Surg. 2019 May 16. pii: S0022-5223(19)31004.
    PubMed     Text format    


    J Thorac Oncol

  26. IAMS WT, Shiuan E, Meador CB, Roth M, et al
    Improved prognosis and increased tumor infiltrating lymphocytes in small cell lung cancer patients with neurologic paraneoplastic syndromes.
    J Thorac Oncol. 2019 Jun 12. pii: S1556-0864(19)30463.
    PubMed     Text format     Abstract available

  27. AGGARWAL C, Redman MW, Lara PN Jr, Borghaei H, et al
    Brief Report: SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously-treated Patients with Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
    J Thorac Oncol. 2019 Jun 10. pii: S1556-0864(19)30462.
    PubMed     Text format     Abstract available

  28. LAIRD J, Lok BH, Carney B, Kossatz S, et al
    PET Imaging of a [(18)F]-radiolabeled PARP Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in Small Cell Lung Cancer Patient-Derived Xenografts.
    J Thorac Oncol. 2019 Jun 10. pii: S1556-0864(19)30453.
    PubMed     Text format     Abstract available

  29. GIAJLEVRA N, Levra MG, Durieux V, Novello S, et al
    Defining synchronous oligometastatic non-small cell lung cancer: a systematic review.
    J Thorac Oncol. 2019 Jun 10. pii: S1556-0864(19)30458.
    PubMed     Text format     Abstract available

  30. KIM Y, Kim CH, Lee HY, Lee SH, et al
    Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor.
    J Thorac Oncol. 2019 Jun 10. pii: S1556-0864(19)30454.
    PubMed     Text format     Abstract available


    Lung Cancer

  31. KSIENSKI D, Wai ES, Croteau N, Freeman AT, et al
    Pembrolizumab for advanced nonsmall cell lung cancer: Efficacy and safety in everyday clinical practice.
    Lung Cancer. 2019;133:110-116.
    PubMed     Text format     Abstract available

  32. AWAD MM, Leonardi GC, Kravets S, Dahlberg SE, et al
    Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis.
    Lung Cancer. 2019;133:96-102.
    PubMed     Text format     Abstract available

  33. PETERS S, Felip E, Dafni U, Belka C, et al
    Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial.
    Lung Cancer. 2019;133:83-87.
    PubMed     Text format     Abstract available

  34. LI X, Zhang C, Sun Z, Yang F, et al
    Propensity-matched analysis of adjuvant chemotherapy for completely resected Stage IB non-small-cell lung cancer patients.
    Lung Cancer. 2019;133:75-82.
    PubMed     Text format     Abstract available

  35. TSAKONAS G, Botling J, Micke P, Rivard C, et al
    c-MET as a biomarker in patients with surgically resected non-small cell lung cancer.
    Lung Cancer. 2019;133:69-74.
    PubMed     Text format     Abstract available

  36. LOWENSTEIN M, Vijayaraghavan M, Burke NJ, Karliner L, et al
    Real-world lung cancer screening decision-making: Barriers and facilitators.
    Lung Cancer. 2019;133:32-37.
    PubMed     Text format     Abstract available

  37. MORABITO A, Piccirillo MC, Maione P, Luciani A, et al
    Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell lung cancer: Joint analysis of MILES-3 and MILES-4 randomised phase 3 trials.
    Lung Cancer. 2019;133:62-68.
    PubMed     Text format     Abstract available

  38. DIMOU A, Bamias A, Gogas H, Syrigos K, et al
    Inhibition of the Hedgehog pathway in lung cancer.
    Lung Cancer. 2019;133:56-61.
    PubMed     Text format     Abstract available

  39. MELOSKY B, Bradbury P, Tu D, Florescu M, et al
    Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group
    Lung Cancer. 2019;133:48-55.
    PubMed     Text format     Abstract available

  40. SAKIN A, Sahin S, Yasar N, Demir C, et al
    Prognostic impact of blood transfusion in patients with metastatic non-small cell lung cancer receiving chemotherapy.
    Lung Cancer. 2019;133:38-44.
    PubMed     Text format     Abstract available

  41. AREDO JV, Padda SK, Kunder CA, Han SS, et al
    Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes.
    Lung Cancer. 2019;133:144-150.
    PubMed     Text format     Abstract available

  42. SHINDE A, Horne ZD, Li R, Glaser S, et al
    Optimal adjuvant therapy in clinically N2 non-small cell lung cancer patients undergoing neoadjuvant chemotherapy and surgery: The importance of pathological response and lymph node ratio.
    Lung Cancer. 2019;133:136-143.
    PubMed     Text format     Abstract available

  43. DEGENS JHRJ, Sanders KJC, de Jong EEC, Groen HJM, et al
    The prognostic value of early onset, CT derived loss of muscle and adipose tissue during chemotherapy in metastatic non-small cell lung cancer.
    Lung Cancer. 2019;133:130-135.
    PubMed     Text format     Abstract available

  44. ROMERO-VIELVA L, Viteri S, Moya-Horno I, Toscas JI, et al
    Salvage surgery after definitive chemo-radiotherapy for patients with Non-Small Cell Lung Cancer.
    Lung Cancer. 2019;133:117-122.
    PubMed     Text format     Abstract available

  45. FUJIMOTO D, Yomota M, Sekine A, Morita M, et al
    Nivolumab for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia: A multicenter, open-label single-arm phase II trial.
    Lung Cancer. 2019 Jun 3. pii: S0169-5002(19)30494.
    PubMed     Text format     Abstract available

  46. GAYE E, Geier M, Bore P, Guilloique M, et al
    Intra-cranial efficacy of brigatinib in an ALK-positive non-small cell lung cancer patient presenting leptomeningeal carcinomatosis.
    Lung Cancer. 2019;133:1-3.
    PubMed     Text format     Abstract available


    Nat Rev Cancer

  47. RUDIN CM, Poirier JT, Byers LA, Dive C, et al
    Author Correction: Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data.
    Nat Rev Cancer. 2019 Jun 7. pii: 10.1038/s41568-019-0164.
    PubMed     Text format     Abstract available


    PLoS One

  48. WALTER J, Tufman A, Holle R, Schwarzkopf L, et al
    "Age matters"-German claims data indicate disparities in lung cancer care between elderly and young patients.
    PLoS One. 2019;14:e0217434.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: